Your browser doesn't support javascript.
loading
Efficacy and Safety of Rezivertinib (BPI-7711) in Patients With Locally Advanced or Metastatic/Recurrent EGFR T790M-Mutated NSCLC: A Phase 2b Study.
Shi, Yuankai; Wu, Shiman; Wang, Ke; Cang, Shundong; Yao, Wenxiu; Fan, Yun; Wu, Lin; Huang, Meijuan; Li, Xingya; Pan, Yueyin; Yang, Zhixiong; Zhu, Bo; Chen, Gongyan; Shi, Jianhua; Sun, Meili; Fang, Jian; Wang, Lijun; Chen, Zhaohong; Liu, Chunling; Li, Jingzhang; Liu, Jiwei; Sun, Shenghua; Zhao, Yanqiu; Guo, Yanzhen; Meng, Zili; Liu, Zhefeng; Han, Zhigang; Lu, Hong; Ma, Rui; Hu, Sheng; Zhao, Guofang; Liu, Zheng; Xie, Congying; Zhong, Diansheng; Zhao, Hui; Yu, Huiqing; Zhang, Longzhen; Bi, Minghong; Yi, Shanyong; Guo, Shuliang; Yi, Tienan; Li, Wen; Lin, Yingcheng; Shu, Yongqian; Chen, Zhendong; Guo, Zhongliang; Greco, Michael; Wang, Tingting; Shen, Haijiao.
Affiliation
  • Shi Y; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, People's Republic of
  • Wu S; Department of Respiratory Medicine, The First Hospital of Shanxi Medical Univers, Taiyuan, People's Republic of China.
  • Wang K; Department of Respiratory and Critical Care Medicine, West China Hospital of Sichuan University, Chengdu, People's Republic of China.
  • Cang S; Department of Medical Oncology, Henan Provincial People's Hospital, Zhengzhou, People's Republic of China.
  • Yao W; Department of Medical Oncology, Sichuan Cancer Hospital, Chengdu, People's Republic of China.
  • Fan Y; Department of Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, People's Republic of China.
  • Wu L; Department of Thoracic Medical Oncology, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, People's Republic of China.
  • Huang M; Department of Oncology, West China Hospital of Sichuan University, Chengdu, People's Republic of China.
  • Li X; Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, People's Republic of China.
  • Pan Y; Department of Thoracic Cancer Chemotherapy, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, People's Republic of China.
  • Yang Z; Cancer Center, Affiliated Hospital of Guangdong Medical University, Zhanjiang, People's Republic of China.
  • Zhu B; Department of Oncology, Institute of Cancer, Xinqiao Hospital, Third Military Medical University, Chongqing, People's Republic of China.
  • Chen G; Department of Respiratory Medicine, Harbin Medical University Cancer Hospital, Harbin, People's Republic of China.
  • Shi J; Department of Medical Oncology, Linyi Cancer Hospital, Linyi, People's Republic of China.
  • Sun M; Department of Oncology, Ji'nan Central Hospital Shandong University, Jinan, People's Republic of China.
  • Fang J; Department of Thoracic Oncology, Beijing Cancer Hospital, Beijing, People's Republic of China.
  • Wang L; Cancer Center, The Second Affiliated Hospital of Xingtai Medical College, Xingtai, People's Republic of China.
  • Chen Z; Department of Oncology, People's Hospital of Deyang City, Deyang, People's Republic of China.
  • Liu C; Pulmonary Cancer Medicine, Affiliated Tumor Hospital of Xinjiang Medical University, Urumqi, People's Republic of China.
  • Li J; Department of Oncology, Liuzhou People's Hospital, Liuzhou, People's Republic of China.
  • Liu J; Department of Oncology, The First Affiliated Hospital of Dalian Medical University, Dalian, People's Republic of China.
  • Sun S; Department of Respiratory Medicine, Third Xiangya Hospital of Central South University, Changsha, People's Republic of China.
  • Zhao Y; Department of Respiratory Medicine, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, People's Republic of China.
  • Guo Y; Department of Medical Oncology, The First Affiliated Hospital of Henan University of Science & Technology, Luoyang, People's Republic of China.
  • Meng Z; Department of Respiratory Medicine, The Affiliated Huai'an No. 1 People's Hospital of Nanjing Medical University, Huai'an, People's Republic of China.
  • Liu Z; Department of Oncology, Chinese PLA General Hospital, Beijing, People's Republic of China.
  • Han Z; Pulmonary Cancer Medicine, Affiliated Tumor Hospital of Xinjiang Medical University, Urumqi, People's Republic of China.
  • Lu H; Department of Oncology, Huaihe Hospital of Henan University, Kaifeng, People's Republic of China.
  • Ma R; Department of Thoracic Oncology, Liaoning Cancer Hospital & Institute, Shenyang, People's Republic of China.
  • Hu S; Department of Thoracic Oncology, Hubei Cancer Hospital, Wuhan, People's Republic of China.
  • Zhao G; Department of Thoracic Surgery, Hwa Mei Hospital, University of Chinese Academy of Sciences, Ningbo, People's Republic of China.
  • Liu Z; Department of Oncology, Handan Central Hospital, Handan, People's Republic of China.
  • Xie C; Department of Radiotherapy, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, People's Republic of China.
  • Zhong D; Department of Medical Oncology, Tianjin Medical University General Hospital, Tianjin, People's Republic of China.
  • Zhao H; Department of Respiratory Medicine, The Second Hospital of Anhui Medical University, Hefei, People's Republic of China.
  • Yu H; Department of Palliative Care, Department of Geriatric Oncology, Chongqing University Cancer Hospital, Chongqing, People's Republic of China.
  • Zhang L; Department of Radiotherapy, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, People's Republic of China.
  • Bi M; Department of Medical Oncology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, People's Republic of China.
  • Yi S; Department of Medical Oncology, Zhengzhou Central Hospital Affiliated to Zhengzhou University, Zhengzhou, People's Republic of China.
  • Guo S; Department of Respiratory Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing, People's Republic of China.
  • Yi T; Department of Oncology, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Sciences, Xiangyang, People's Republic of China.
  • Li W; Department of Respiratory and Critical Care Medicine, The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, People's Republic of China.
  • Lin Y; Department of Medical Oncology, Cancer Hospital of Shantou University Medical College, Shantou, People's Republic of China.
  • Shu Y; Department of Oncology, Jiangsu Province Hospital, Nanjing, People's Republic of China.
  • Chen Z; Department of Oncology, The Second Hospital of Anhui Medical University, Hefei, People's Republic of China.
  • Guo Z; Department of Respiratory Medicine, Shanghai East Hospital, Shanghai, People's Republic of China.
  • Greco M; Department of Drug Discovery, Beta Pharma Inc., Princeton, New Jersey.
  • Wang T; Department of Clinical Development, Beta Pharma (Shanghai) Co., Ltd., Shanghai, People's Republic of China.
  • Shen H; Department of Clinical Development, Beta Pharma (Shanghai) Co., Ltd., Shanghai, People's Republic of China.
J Thorac Oncol ; 17(11): 1306-1317, 2022 11.
Article de En | MEDLINE | ID: mdl-36049654

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Carcinome pulmonaire non à petites cellules / Tumeurs du poumon / Antinéoplasiques Limites: Humans Langue: En Journal: J Thorac Oncol Année: 2022 Type de document: Article Pays de publication: États-Unis d'Amérique

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Carcinome pulmonaire non à petites cellules / Tumeurs du poumon / Antinéoplasiques Limites: Humans Langue: En Journal: J Thorac Oncol Année: 2022 Type de document: Article Pays de publication: États-Unis d'Amérique